Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-02-20
2009-02-10
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07488712
ABSTRACT:
Compounds represented by formula (1) have strong inhibitory activity that is selective towards HDAC1 and HDAC4. Therefore, the compounds of the present invention are useful as pharmaceutical agents for treating or preventing diseases caused by HDAC1 and HDAC4.
REFERENCES:
patent: 6399568 (2002-06-01), Nishino et al.
patent: 2002/0120099 (2002-08-01), Nishino et al.
patent: 2003/0078369 (2003-04-01), Meinke et al.
patent: 2007/0185071 (2007-08-01), Yoshida et al.
patent: 2 317 003 (2001-08-01), None
patent: 1 174 438 (2002-01-01), None
patent: 1 174 438 (2002-01-01), None
patent: 11-130795 (1999-05-01), None
patent: 2000-256397 (2000-09-01), None
patent: 2000256397 (2000-09-01), None
patent: 2001316283 (2001-11-01), None
patent: 2002527449 (2002-08-01), None
patent: 2003-505417 (2003-02-01), None
patent: 2003505417 (2003-02-01), None
patent: WO 00/21979 (2000-04-01), None
patent: WO 00/52033 (2000-09-01), None
patent: WO 01/07042 (2001-02-01), None
patent: WO 03/057722 (2003-07-01), None
patent: WO 03/070754 (2003-08-01), None
Rich DH, “Synthesis of dehydro amino acids and peptides by dehydrosulfenylation. Rate enhancement using sulfenic acid trapping agents,” J Org Chem. Nov. 25, 1977;42(24):3815-20.
Answer 15 of 17 HCAPLUS, two pages from search report.
Robertson KD., “DNA methylation and chromatin—unraveling the tangled web. Oncogene,” Aug. 12, 2002;21(35):5361-79.
Bernhard et al., “Interaction between dexamethasone and butyrate in apoptosis induction: non-additive in thymocytes and synergistic in a T cell-derived leukemia cell line,”Cell Death and Differentiation, 1999, 6(7):609-617.
Boivin et al., “Antineoplastic action of 5-aza-2′-deoxycytidine and phenylbutyrate on human lung carcinoma cells,”Anti-Cancer Drugs, 2002, 13(8):869-874.
Cameron et al., “Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer,”Nature Genetics, 1999, 21(1):103-107.
Chen et al., “Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase,”Proc. Natl. Acad. Sci. USA, 1997, 94:5798-5803.
Coffey et al., “The Histone Deacetylase Inhibitor, CBHA, Inhibits Growth of Human Neuroblastoma Xenografts in Vivo, Alone and Synergistically withAll-TransRetinoic Acid,”Cancer Research, 2001, 61(9):3591-3594.
Colletti et al., “Broad Spectrum Antiprotozoal Agents that Inhibit Histone Deacetylase: Structure-Activity Relatinships of Apicidin. Part 2,”Bioorganic&Medicinal Chemistry Letters, 2001, 11:113-117.
Colletti et al, “Design and synthesis of histone deacetylase inhibitors: the development of apicidin transition state analogs,”Tetrahedron Letters, 2000, 41:7837-7841.
Darkin-Rattray et al., “Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase,”Proc. Natl. Acad. Sci. USA, 1996, 93:13143-13147.
Dhordain et al., “Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein,”Proc. Natl. Acad. Sci. USA, 1997, 94:10762-10767.
Dion et al., “Amplification of Recombinant Adenoviral Transgene Products Occurs by Inhibition of Histone Deacetylase,”Virology, 1997, 231:201-209.
Ferrara et al., “Histone Deacetylase-targeted Treatment Restores Retinoic Acid Signaling and Differentiation in Acute Myeloid Leukemia,”Cancer Research, 2001, 61(1):2-7.
Finnin et al., “Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors,”Nature, 1999, 401:188-193.
Fischle et al., “A New Family of Human Histone Deacetylases Related toSaacharomyces cerevisiae, HDA1p,”J. Biol. Chem., 1999, 274(17):11713-11720.
Furumai et al., “Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin,”Proc. Natl. Acad. Sci. USA, 2001, 98(1):87-92.
Furumai et al., “FK228 (Depsipeptide) as a Natural Prodrug That Inhibits Class I Histone Deacetylases,”Cancer Research, 2002, 62(17):4916-4921.
Göttlicher et al., “Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells,”EMBO J., 2001, 20(24):6969-6978.
Grignani et al., “Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia,”Nature, 1998, 391:815-818.
He et al., “Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL,”Nature Genetics, 1998, 18:126-134.
Hoshikawa et al., “Expression of Differentiation-related Markers in Teratocarcinoma Cells via Histone Hyperacetylation by Trichostatin A,”Agric. Biol. Chem., 1991, 55(6):1491-1495.
Hubbert et al., “HDAC6 is a microtubule-associated deacetylase,”Nature, 2002, 417:455-458.
Inokoshi et al., “Neuronal Differentiation of Neuro 2a Cells by Inhibitors of Cell Cycle Progression, Trichostatin A and Butyrolactone I,”Biochem. Biophys. Res. Comm., 1999, 256(2):372-376.
Ito et al., “p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2,”EMBO J., 2001, 20(6):1331-1340.
Juan et al., “Histone Deacetylases Specifically Down-regulate p53-dependent Gene Activation,”J. Biol. Chem., 2000, 275(27):20436-20443.
Kim et al., “Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase,”Oncogene, 1999, 18:2461-2470.
Kim et al., “Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes,”Nature Medicine, 2001, 7(4):437-443.
Komatsu et al., “Cyclic Hydroxamic-acid-containing Peptide 31, a Potent Synthetic Histone Deacetylase Inhibitor with Antitumor Activity,”Cancer Research, 2001, 61(11):4459-4466.
Kwon et al., “Histone Deacetylase Inhibitor FK228 Inhibits Tumor Angiogenesis,”Int. J. Cancer, 2002, 97:290-296.
Li et al., “Casual Relationship between the Loss ofRUNX3Expression and Gastric Cancer,”Cell, 2002, 109(1):113-124.
Lin et al., “Role of the histone deacetylase complex in acute promyelocytic leukaemia,”Nature, 1998, 391:811-814.
Marks et al., “Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells,”J. Natl. Cancer Inst., 2000, 92:1210-1216.
Matsuyama et al., “In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation,”EMBO J., 2002, 21(24):6820-6831.
Meinke et al., “Synthesis of side chain modified apicidin derivatives: potent mechanism-based histone deacetylase inhibitors,”Tetrahedron Letters, 2000, 41:7831-7835.
McKinsey et al., “Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation,”Nature, 2000, 408:106-111.
Minucci et al., “A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells,”Proc. Natl. Acad. Sci. USA, 1997, 94(21):11295-11300.
Munster et al., “The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Induces Differentiation of Human Breast Cancer Cells,”Cancer Research, 2001, 61(23):8492-8497.
Nakajima et al., “FR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase Inhibitor,”Exp. Cell Res., 1998, 241(1):126-133.
Nan et al., “Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex,”Nature, 1998, 393(6683):386-389.
Petti et al., “Complete remission through blast cell differentiation inPLZF/RARα-positive acute promyelocytic leukemia: in vitro and in vivo studies,”Blood, 2002, 100(3):1065-1067.
Primeau et al., “Synergistic Antineoplastic Action of DNA Methylation Inhibitor 5-AZA-2′-Deoxycytidine and Histone Deacetylase Inhibitor Depsipeptide on Human Breast Carcinoma Cells,”Int. J. Cancer, 2003,
Horinouchi Sueharu
Nishino Norikazu
Yoshida Minoru
Fish & Richardson P.C.
Gupta Anish
Heard Thomas S
Kyushu Institute of Technology
LandOfFree
Histone deacetylase inhibitors and methods for producing the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Histone deacetylase inhibitors and methods for producing the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Histone deacetylase inhibitors and methods for producing the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4098125